|Dr. Martin Welschof Ph.D.||President & CEO||5.06M||N/A||1961|
|Mr. Stefan Ericsson M.B.A.||Chief Financial Officer||N/A||N/A||1963|
|Ms. Marie Moores M.Sc., R.G.N.||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Kristoffer Rudenholm Hansson||Senior Vice President of Technical Operations||N/A||N/A||1974|
|Mr. Björn Frendéus||Chief Scientific Officer||2.35M||N/A||1973|
|Ms. Cecilia Hofvander||Senior Director of Investor Relations||N/A||N/A||1967|
|Dr. Andres McAllister||Chief Medical Officer||N/A||N/A||1956|
|Ms. Ingrid Teige||Head of Preclinical Research||N/A||N/A||N/A|
|Ms. Sylvie Ryckebusch||Chief Business Officer||N/A||N/A||N/A|
|Dr. Ingunn Munch Lindvig||Senior Vice President of Regulatory Affairs||N/A||N/A||N/A|
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
BioInvent International AB (publ)’s ISS governance QualityScore as of 28 November 2023 is 5. The pillar scores are Audit: 9; Board: 2; Shareholder rights: 1; Compensation: 9.